NYC lawyer James Medows confirms standard equipment violations remain point-free, offering vital relief for drivers ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes ...
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and ...
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results